Insider trades › RA Capital Healthcare Fund LP
RA Capital Healthcare Fund LP
A corporate insider: an officer, director or owner of more than 10% of a company. Insiders report their trades to the SEC on Form 4The form insiders use to report each purchase or sale of their company's stock. It is due within two business days of the trade. · Last filing Aug 26, 2026
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, list RA Capital Healthcare Fund LP's open-market buys and sells across companies in the last two years, with the Form 4 links.
Using 13F.ai, how did the stocks RA Capital Healthcare Fund LP bought perform after the purchase compared with the S&P 500?
Using 13F.ai, are other insiders at the same companies buying or selling at the same time as RA Capital Healthcare Fund LP?
Connect your AI · Plans and the 7-day free trial (card required)
Buying and selling by quarter
Dollars bought and sold on the open market over the last two years.
Bought Sold
By trade date, using the shares and price reported for each trade. Stock grants, option exercises and shares withheld for tax are left out.
Roles
The companies where this person reports as an insider, and their position at each, most recent first.
| VOR Vor Biopharma Inc. | 10% owner | Aug 26, 2026 |
| IKT Inhibikase Therapeutics, Inc. | 10% owner | Jul 31, 2026 |
| ARTV Artiva Biotherapeutics, Inc. | Director, 10% owner | Jul 31, 2026 |
| PBLS Parabilis Medicines, Inc. | Director | Jun 11, 2026 |
| TYRA Tyra Biosciences, Inc. | Director, 10% owner | Jun 1, 2026 |
| COAG Hemab Therapeutics Holdings, Inc. | 10% owner | May 11, 2026 |
| ACET Adicet Bio, Inc. | 10% owner | Apr 13, 2026 |
| MLYS Mineralys Therapeutics, Inc. | Director | Feb 20, 2026 |
| EVMN Evommune, Inc. | Director | Feb 17, 2026 |
| SGP SpyGlass Pharma, Inc. | Director, 10% owner | Feb 11, 2026 |
| CDTX Cidara Therapeutics, Inc. | Director, 10% owner | Jan 9, 2026 |
| CLYM Climb Bio, Inc. | Director, 10% owner | Jan 7, 2026 |
| FULC Fulcrum Therapeutics, Inc. | 10% owner | Dec 10, 2025 |
| PEPG PepGen Inc. | Director, 10% owner | Sep 30, 2025 |
| WVE Wave Life Sciences, Inc. | Director, 10% owner | Aug 13, 2025 |
| SEPN Septerna, Inc. | Director, 10% owner | Jun 20, 2025 |
| JANX Janux Therapeutics, Inc. | Director, 10% owner | Jun 13, 2025 |
| LENZ LENZ Therapeutics, Inc. | Director, 10% owner | Jun 11, 2025 |
| NKTX Nkarta, Inc. | Director, 10% owner | Jun 9, 2025 |
| ABOS Acumen Pharmaceuticals, Inc. | Director, 10% owner | Jun 5, 2025 |
| ETNB 89bio, Inc. | Director, 10% owner | Feb 5, 2025 |
Roles come from the filings themselves and can change over time.
Latest open-market trades
Purchases and sales at every company, most recent filing first.
| How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss. | Filing | ||||||
|---|---|---|---|---|---|---|---|
| Jul 31, 2026 | ARTV Artiva Biotherapeutics, Inc. | Buy | 24,944 | $9.93 | $247.7K | -61.3% | Form 4 ↗ |
| Jul 29, 2026 | ARTV Artiva Biotherapeutics, Inc. | Buy | 20,824 | $9.99 | $208.0K | -63.4% | Form 4 ↗ |
| Jul 17, 2026 | ARTV Artiva Biotherapeutics, Inc. | Buy | 7,882 | $8.95 | $70.5K | -60.4% | Form 4 ↗ |
| Jul 16, 2026 | ARTV Artiva Biotherapeutics, Inc. | Buy | 152,472 | $8.93 | $1.4M | -56.1% | Form 4 ↗ |
| May 11, 2026 | COAG Hemab Therapeutics Holdings, Inc. | Buy | 25,720 | $25.00 | $643.0K | +61.4% | Form 4 ↗ |
| May 11, 2026 | COAG Hemab Therapeutics Holdings, Inc. | Buy | 14,149 | $24.47 | $346.2K | +61.4% | Form 4 ↗ |
| May 8, 2026 | COAG Hemab Therapeutics Holdings, Inc. | Buy | 1,483 | $24.98 | $37.0K | +60.4% | Form 4 ↗ |
| May 7, 2026 | COAG Hemab Therapeutics Holdings, Inc. | Buy | 1,985 | $24.95 | $49.5K | +55.6% | Form 4 ↗ |
| May 7, 2026 | COAG Hemab Therapeutics Holdings, Inc. | Buy | 7,921 | $24.34 | $192.8K | +55.6% | Form 4 ↗ |
| Feb 20, 2026 | ACET Adicet Bio, Inc. | Buy | 74,751 | $7.27 | $543.4K | -70.5% | Form 4 ↗ |
| Feb 19, 2026 | ACET Adicet Bio, Inc. | Buy | 74,268 | $7.21 | $535.5K | -72.8% | Form 4 ↗ |
| Feb 18, 2026 | ACET Adicet Bio, Inc. | Buy | 74,577 | $7.04 | $525.0K | -70.5% | Form 4 ↗ |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | Buy | 3.44M | $16.00 | $55.1M | +16.9% | Form 4 ↗ |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | Buy | 248,034 | $16.00 | $4.0M | +16.9% | Form 4 ↗ |
| Jan 5, 2026 | CLYM Climb Bio, Inc. | Buy | 7,111 | $3.50 | $24.9K | +183.0% | Form 4 ↗ |
| Dec 8, 2025 | FULC Fulcrum Therapeutics, Inc. | Sale | 1.38M | $13.33 | $18.4M | -81.3% | Form 4 ↗ |
| Dec 8, 2025 | FULC Fulcrum Therapeutics, Inc. | Sale | 2.71M | $14.28 | $38.6M | -81.3% | Form 4 ↗ |
| Dec 8, 2025 | FULC Fulcrum Therapeutics, Inc. | Sale | 91,722 | $14.98 | $1.4M | -81.3% | Form 4 ↗ |
| Sep 26, 2025 | PEPG PepGen Inc. | Buy | 9.38M | $3.20 | $30.0M | -28.0% | Form 4 ↗ |
| Jun 9, 2025 | TYRA Tyra Biosciences, Inc. | Buy | 186,850 | $10.19 | $1.9M | +69.4% | Form 4 ↗ |
| Mar 7, 2025 | JANX Janux Therapeutics, Inc. | Buy | 110,206 | $31.02 | $3.4M | -93.9% | Form 4 ↗ |
| Mar 6, 2025 | JANX Janux Therapeutics, Inc. | Buy | 372,093 | $30.78 | $11.5M | -94.7% | Form 4 ↗ |
| Mar 5, 2025 | JANX Janux Therapeutics, Inc. | Buy | 304,287 | $30.56 | $9.3M | -93.3% | Form 4 ↗ |
| Mar 5, 2025 | JANX Janux Therapeutics, Inc. | Buy | 37,455 | $31.30 | $1.2M | -93.3% | Form 4 ↗ |
| Nov 8, 2024 | TYRA Tyra Biosciences, Inc. | Buy | 1.22M | $16.25 | $19.8M | -1.8% | Form 4 ↗ |
Each row links to its Form 4. Since trade compares the stock’s move from the close on the trade date (or the next trading day) to its latest close with the S&P 500 over the same days, adjusted for splits and excluding dividends. It describes the stock, not what the trader made: we don’t know their purchase price, position size or later sales. A dash means the trade isn’t matched to a listed stock, or there is no closing price after it yet.
When several people report on the same filing, we list it under the first one named, so trades by someone usually listed second may be missing here. Information, not investment advice: see the disclaimer.